# GRI Bio, Inc.: financial statements, quarterly

GRI · Nasdaq · CIK 1824293 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gri.md) · [Financials](/companies/gri/financials.md) · [Filings](/companies/gri/filings.md) · [Insiders](/companies/gri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gri/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,189](/filings/0001824293-24-000151.md) | [1,046 d](/filings/0001824293-25-000050.md) | [933](/filings/0001824293-25-000073.md) | [877](/filings/0001824293-25-000106.md) | [1,125](/filings/0001824293-25-000151.md) | [907 d](/filings/0001824293-26-000033.md) | [1,640](/filings/0001824293-26-000044.md) | [1,879](/filings/0001824293-26-000055.md) | [1,769](/filings/0001824293-25-000151.md) | [1,631 d](/filings/0001824293-26-000033.md) | [361](/filings/0001824293-26-000044.md) | [407](/filings/0001824293-26-000055.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(2,439)](/filings/0001824293-24-000151.md) | [(2,026) d](/filings/0001824293-25-000050.md) | [(1,895)](/filings/0001824293-25-000073.md) | [(2,257)](/filings/0001824293-25-000106.md) | [(2,130)](/filings/0001824293-25-000151.md) | [(1,954) d](/filings/0001824293-26-000033.md) | [(3,051)](/filings/0001824293-26-000044.md) | [(2,897)](/filings/0001824293-26-000055.md) | [(3,365)](/filings/0001824293-25-000151.md) | [(2,664) d](/filings/0001824293-26-000033.md) | [(2,003)](/filings/0001824293-26-000044.md) | [(1,648)](/filings/0001824293-26-000055.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,137)](/filings/0001824293-24-000151.md) | [(2,004) d](/filings/0001824293-25-000050.md) | [(1,887)](/filings/0001824293-25-000151.md) | [(2,250)](/filings/0001824293-25-000151.md) | [(2,123)](/filings/0001824293-25-000151.md) | [(1,948) d](/filings/0001824293-26-000033.md) | [(3,046)](/filings/0001824293-26-000055.md) | [(2,892)](/filings/0001824293-26-000055.md) | [(3,359)](/filings/0001824293-25-000151.md) | [(2,659) d](/filings/0001824293-26-000033.md) | [(1,998)](/filings/0001824293-26-000055.md) | [(1,643)](/filings/0001824293-26-000055.md) |
| Diluted EPS | $ per share | [(65.78)](/filings/0001824293-24-000151.md) | not reported | [(101.05)](/filings/0001824293-25-000073.md) | [(61.85)](/filings/0001824293-25-000106.md) | [(11.42)](/filings/0001824293-25-000151.md) | not reported | [(162.30)](/filings/0001824293-26-000044.md) | [(36.72)](/filings/0001824293-26-000055.md) | [(1.28)](/filings/0001824293-25-000151.md) | not reported | [(1.61)](/filings/0001824293-26-000044.md) | [(0.91)](/filings/0001824293-26-000055.md) |
| Basic EPS | $ per share | [(65.78)](/filings/0001824293-24-000151.md) | not reported | [(101.05)](/filings/0001824293-25-000073.md) | [(61.85)](/filings/0001824293-25-000106.md) | [(11.42)](/filings/0001824293-25-000151.md) | not reported | [(162.30)](/filings/0001824293-26-000044.md) | [(36.72)](/filings/0001824293-26-000055.md) | [(1.28)](/filings/0001824293-25-000151.md) | not reported | [(1.61)](/filings/0001824293-26-000044.md) | [(0.91)](/filings/0001824293-26-000055.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.5](/filings/0001824293-23-000170.md) | [1.8](/filings/0001824293-25-000050.md) | [4.1](/filings/0001824293-24-000047.md) | [6.4](/filings/0001824293-24-000105.md) | [4.7](/filings/0001824293-24-000151.md) | [5.0](/filings/0001824293-26-000033.md) | [3.3](/filings/0001824293-25-000073.md) | [5.1](/filings/0001824293-25-000106.md) | [4.1](/filings/0001824293-25-000151.md) | [8.2](/filings/0001824293-26-000055.md) | [11.0](/filings/0001824293-26-000044.md) | [10.9](/filings/0001824293-26-000055.md) |
| Current assets | $m | [4.4](/filings/0001824293-23-000170.md) | [2.9](/filings/0001824293-25-000050.md) | [4.4](/filings/0001824293-24-000047.md) | [6.9](/filings/0001824293-24-000105.md) | [5.3](/filings/0001824293-24-000151.md) | [5.6](/filings/0001824293-26-000033.md) | [3.9](/filings/0001824293-25-000073.md) | [5.6](/filings/0001824293-25-000106.md) | [4.7](/filings/0001824293-25-000151.md) | [8.6](/filings/0001824293-26-000055.md) | [11.3](/filings/0001824293-26-000044.md) | [11.3](/filings/0001824293-26-000055.md) |
| Total assets | $m | [4.4](/filings/0001824293-23-000170.md) | [3.0](/filings/0001824293-25-000050.md) | [4.6](/filings/0001824293-24-000047.md) | [7.0](/filings/0001824293-24-000105.md) | [5.5](/filings/0001824293-24-000151.md) | [5.7](/filings/0001824293-26-000033.md) | [4.0](/filings/0001824293-25-000073.md) | [5.7](/filings/0001824293-25-000106.md) | [4.8](/filings/0001824293-25-000151.md) | [8.7](/filings/0001824293-26-000055.md) | [11.3](/filings/0001824293-26-000044.md) | [11.4](/filings/0001824293-26-000055.md) |
| Current liabilities | $m | [2.2](/filings/0001824293-23-000170.md) | [2.7](/filings/0001824293-25-000050.md) | [1.7](/filings/0001824293-24-000047.md) | [2.2](/filings/0001824293-24-000105.md) | [1.7](/filings/0001824293-24-000151.md) | [1.6](/filings/0001824293-26-000033.md) | [2.8](/filings/0001824293-25-000073.md) | [2.3](/filings/0001824293-25-000106.md) | [2.8](/filings/0001824293-25-000151.md) | [2.6](/filings/0001824293-26-000055.md) | [0.8](/filings/0001824293-26-000044.md) | [1.1](/filings/0001824293-26-000055.md) |
| Total liabilities | $m | [2.2](/filings/0001824293-23-000170.md) | [2.7](/filings/0001824293-25-000050.md) | [1.8](/filings/0001824293-24-000047.md) | [2.3](/filings/0001824293-24-000105.md) | [1.8](/filings/0001824293-24-000151.md) | [1.7](/filings/0001824293-26-000033.md) | [2.8](/filings/0001824293-25-000073.md) | [2.4](/filings/0001824293-25-000106.md) | [2.8](/filings/0001824293-25-000151.md) | [2.7](/filings/0001824293-26-000055.md) | [0.8](/filings/0001824293-26-000044.md) | [1.1](/filings/0001824293-26-000055.md) |
| Shareholders' equity | $m | [2.2](/filings/0001824293-24-000151.md) | [0.3](/filings/0001824293-26-000033.md) | [2.8](/filings/0001824293-25-000151.md) | [4.7](/filings/0001824293-25-000151.md) | [3.7](/filings/0001824293-25-000151.md) | [4.0](/filings/0001824293-26-000055.md) | [1.2](/filings/0001824293-26-000055.md) | [3.3](/filings/0001824293-26-000055.md) | [2.0](/filings/0001824293-25-000151.md) | [6.0](/filings/0001824293-26-000055.md) | [10.5](/filings/0001824293-26-000055.md) | [10.3](/filings/0001824293-26-000055.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,311) d](/filings/0001824293-24-000151.md) | [(5,560) d](/filings/0001824293-25-000050.md) | [(2,203)](/filings/0001824293-25-000073.md) | [(2,141) d](/filings/0001824293-25-000106.md) | [(2,268) d](/filings/0001824293-25-000151.md) | [(1,999) d](/filings/0001824293-26-000033.md) | [(1,736)](/filings/0001824293-26-000044.md) | [(3,166) d](/filings/0001824293-26-000055.md) | [(2,313) d](/filings/0001824293-25-000151.md) | [(2,971) d](/filings/0001824293-26-000033.md) | [(3,685)](/filings/0001824293-26-000044.md) | [(1,446) d](/filings/0001824293-26-000055.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001824293-24-000151.md) | [0.0 d](/filings/0001824293-25-000050.md) | not reported | not reported | [0.0 d](/filings/0001824293-24-000151.md) | [0.0 d](/filings/0001824293-26-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [896](/filings/0001824293-23-000170.md) | [143](/filings/0001824293-24-000047.md) | [28.2](/filings/0001824293-24-000105.md) | [32.5](/filings/0001824293-24-000151.md) | [18.7](/filings/0001824293-25-000073.md) | [36.4](/filings/0001824293-25-000106.md) | [186](/filings/0001824293-25-000151.md) | [18.8](/filings/0001824293-26-000044.md) | [78.8](/filings/0001824293-26-000055.md) | [2,621](/filings/0001824293-25-000151.md) | [1,241](/filings/0001824293-26-000044.md) | [1,805](/filings/0001824293-26-000055.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,186,115 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001824293-26-000055.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.